ProQR Therapeutics (PRQR) Total Non-Current Liabilities (2013 - 2026)
ProQR Therapeutics (PRQR) posted Total Non-Current Liabilities of $30.9 million for Q1 2026, down 14.26% sequentially from $36.0 million in Q4 2025, and down 24.79% YoY from $41.1 million in Q1 2025.
ProQR Therapeutics (PRQR) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
ProQR Therapeutics has reported Total Non-Current Liabilities for 14 years, with the latest figure at $30.9 million in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 24.79% year-over-year to $30.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.9 million (down 24.79% YoY) and the FY2025 annual result came in at $36.0 million, down 16.77% from the prior year.
- Total Non-Current Liabilities fell to $30.9 million in Q1 2026 per PRQR's latest filing, from $36.0 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $85.3 million in Q4 2022 and troughed at $30.9 million in Q1 2026.
- A 5-year average of $48.0 million and a median of $42.4 million in 2025 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities increased 8.51% in 2022, then sank 35.43% in 2024.
- Over 5 years, Total Non-Current Liabilities stood at $85.3 million in 2022, then decreased by 21.47% to $67.0 million in 2023, then plunged by 35.43% to $43.3 million in 2024, then slipped by 16.77% to $36.0 million in 2025, then decreased by 14.26% to $30.9 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $30.9 million, $36.0 million, and $39.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | ProQR Therapeutics | 206.80 Mn | 111.86 Mn | - | 30.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.88 Mn |
| Dec 31, 2025 | 36.02 Mn |
| Sep 30, 2025 | 39.91 Mn |
| Jun 30, 2025 | 42.41 Mn |
| Mar 31, 2025 | 41.06 Mn |
| Dec 31, 2024 | 43.27 Mn |
| Sep 30, 2024 | 46.38 Mn |
| Dec 31, 2023 | 67.02 Mn |
| Dec 31, 2022 | 85.35 Mn |
| Dec 31, 2021 | 78.65 Mn |
| Dec 31, 2020 | 38.01 Mn |
| Dec 31, 2019 | 14.07 Mn |
| Dec 31, 2018 | 10.71 Mn |
| Dec 31, 2017 | 6.22 Mn |
| Dec 31, 2016 | 6.15 Mn |
| Dec 31, 2015 | 5.29 Mn |
| Dec 31, 2014 | 3.54 Mn |
| Dec 31, 2013 | 1.35 Mn |